They are exploring the complex relationship between hormone therapy and neurodegenerative diseases.

About two-thirds of breast cancer patients have tumors that are hormone receptor positive, meaning they grow in response to estrogen or progesterone. In these patients, hypertrophic hormone replacement therapy can prevent tumor growth by preventing hormones from attaching to these receptors. Although the use of hypertrophic hormone replacement therapy is associated with improved survival, there areThere is conflicting evidence about whether it increases or decreases the risk of developing Alzheimer’s disease. and associated dementia (ADRD).

Improving our understanding of ADRD risk following hormone modulating therapy (HMT) in breast cancer patients was the goal of a recent study conducted at the University of Pittsburgh (USA) and published in JAMA Network.

To calculate the risk of developing ADRD, the researchers took into account Risk of death associated with increasing age and duration of TMG exposureThey found that although use of such therapy was associated with an overall reduction in the relative risk of developing ADRD, the protective effect of TMG was most pronounced in patients aged 65 to 69 years and decreased with age. In particular, when patients were over 80 years old, TMG users had an increased risk of developing ADRD.

Pros and cons of TMH

““Our study suggests that younger women may benefit more from hormone replacement therapy in terms of reducing their risk of developing Alzheimer’s disease and other types of dementia,” he pointed out Chao Kai, Associate Professor, University of South Carolina School of Pharmacy“The benefits of hormone replacement therapy declined for women aged 75 years and older, particularly for those who identified as white. This suggests that the timing of initiation of hormone replacement therapy is critical and that treatment plans should be tailored to the patient’s age.

““Our findings highlight the importance of taking individual patient factors into account when prescribing medications or developing treatment plans for breast cancer.”indicated the main author on her part Francescari Modugno, Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh and a member of the Magee Women’s Research Institute and the UPMC Hillman Cancer Center.

In short, according to these authors, The relationship between TMG and breast cancer and dementia risk is complex and it is influenced by many factors”“Further research is needed to better understand the mechanisms underlying this association and provide clearer recommendations for the use of hormone therapy.”, concluded Prof. Kai.